Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) announced its earnings results on Thursday. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.72) by $0.02, AmericanBankingNews.com reports.

A number of analysts have recently weighed in on STML shares. Analysts at Jefferies Group cut their price target on shares of Stemline Therapeutics from $60.00 to $50.00 in a research note on Monday. They now have a “buy” rating on the stock. Analysts at Roth Capital reiterated a “buy” rating on shares of Stemline Therapeutics in a research note on Friday, May 16th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $53.25.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at 13.28 on Thursday. Stemline Therapeutics has a 52 week low of $12.10 and a 52 week high of $47.25. The stock’s 50-day moving average is $15.44 and its 200-day moving average is $21.14. The company’s market cap is $175.9 million.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.